CIPLA vs WOCKPHARMA: Stock Comparison

CIPLA vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

CIPLA is the larger company by market capitalisation. CIPLA shows a lower P/E, a higher dividend yield and lower leverage, while WOCKHARDT shows faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CIPLA leads 8; WOCKPHARMA leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CIPLAWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹1.12 L Cr
₹33,908 Cr
P/E RatioCIPLA has the lower reading
33.86x
75.68x
P/B RatioCIPLA has the lower reading
3.32x
6.27x
EPSCIPLA has the higher reading
₹10.67
₹6.58
Book ValueContext only
₹427.31
₹325
Dividend YieldCIPLA has the higher reading
0.94%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CIPLA is the larger company
₹1.12 L Cr vs ₹33,908 Cr
P/E Ratio
CIPLA has a lower P/E
33.86x vs 75.68x
P/B Ratio
CIPLA has a lower P/B
3.32x vs 6.27x
EPS
CIPLA has higher earnings per share
₹10.67 vs ₹6.58
Dividend Yield
CIPLA has a higher dividend yield
0.94% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -2.1%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -54.6%
Qtr Sales Growth
CIPLA has stronger quarterly sales growth
-28.68% vs -39.61%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAWOCKPHARMA
Live Price₹1,385₹2,088.7
Day Change-0.7%7.08%
Volume13.26 L35.58 L
52-Week High₹1,673₹2,422.3
52-Week Low₹1,165.7₹1,086.7
Distance from 52W High-17.21%-13.77%

Valuation

MetricCIPLAWOCKPHARMA
Market Cap₹1.12 L Cr₹33,908 Cr
P/E Ratio33.86x75.68x
P/B Ratio3.32x6.27x
EPS₹10.67₹6.58
Book Value₹427.31₹325
Dividend Yield0.94%0%

Growth

MetricCIPLAWOCKPHARMA
Revenue Growth (TTM YoY)-2.1%26%
EPS Growth (TTM YoY)-54.6%0%
Qtr Sales Growth-28.68%-39.61%
Qtr Profit Growth9.75%0%

Profitability & Leverage

MetricCIPLAWOCKPHARMA
ROE10.28%10.28%
ROCE10.09%10.37%
Net Margin13.96%3.3%
Operating Margin24.53%28.35%
Debt to Equity0x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCIPLAWOCKPHARMA
Promoter Holding9.17%49.08%
FII Holding20.21% 2.35 pp7.22% 0.13 pp
DII Holding34.63% 2.66 pp9.24% 1.72 pp
Public Holding15.94% 0.31 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CIPLA and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.